I think the idea of 2 BP's working together like that is a great idea. IF leronlimab (or whatever name they will call it) can do all that we think it can for so many indications, there is plenty of pie for everyone, but too much for any one entity to handle, I think.

Someone floated the idea of CYDY owning 40-50% of the acquiring entity, but that makes no sense to me from the point of view that CytoDyn is barely a company, and by that I mean they have no actual infrastructure to do anything beyond making deals for others to sell/market leronlimab. Our management is not set up to actually run a biotech company full-on. The experience and manpower just isn't there. Partnership? Of course!